September 2019

Our September 2019 issue includes partnering companies focused on immuno-oncology, and antibodies among others, showcasing their developments. 

The editorial features cover the ongoing success of monoclonal antibodies, the search for immuno-oncology checkpoint inhibitor partners and how to negotiate a biopharma term sheet.  

We also launch the first of our BioPharma Thought Leader articles, in which we hear from the CEO of Lonza.

About this edition

Read the full September edition here.